Our study revealed significant enrichment of CXCR5+CD4+ and CXCR5+CD8+ T cell in ES-SCLC patients exhibiting robust immunotherapy responses, suggesting their cooperative roles in shaping anti-tumor immunity. Here, CD8A is linked to neoplasm.